Invention Grant
- Patent Title: MEK1 mutation conferring resistance to RAF and MEK inhibitors
-
Application No.: US15011003Application Date: 2016-01-29
-
Publication No.: US09880169B2Publication Date: 2018-01-30
- Inventor: Levi A. Garraway , Caroline Emery , Nikhil Wagle
- Applicant: Levi A. Garraway , Caroline Emery , Nikhil Wagle
- Applicant Address: US MA Boston
- Assignee: Dana-Farber Cancer Institute, Inc.
- Current Assignee: Dana-Farber Cancer Institute, Inc.
- Current Assignee Address: US MA Boston
- Agency: Brinks Gilson & Lione
- Main IPC: G01N33/573
- IPC: G01N33/573 ; G01N33/574 ; C12N9/12 ; C12Q1/68
Abstract:
Nucleic acids and proteins having a mutant MEK sequence, and methods concerning identification of patients having resistance to treatment with anti-cancer agents, specifically inhibitors of RAF or MEK are provided. Methods of treatment and for optimizing treatment for patients having a mutation in a MEK1 sequence are also provided.
Public/Granted literature
- US20160216266A1 MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors Public/Granted day:2016-07-28
Information query
IPC分类:
